Rapamycin (Sirolimus) Cost in New Hampshire 2026

What Does Rapamycin (Sirolimus) Actually Cost in New Hampshire Right Now?

Generic sirolimus at New Hampshire retail pharmacies averages about $80 per month when paid out of pocket in 2026, based on GoodRx pricing aggregated across Concord, Manchester, and Nashua zip codes. The branded Pfizer product Rapamune carries a list price near $600 per month, though almost no cash-paying patient pays that figure. The gap between those two numbers is where most of the practical guidance in this article lives.

The $80 Cash-Pay Benchmark

The $80 figure assumes a 1 mg daily dose (30 tablets of 1 mg). Patients using the more common off-label longevity protocol of 3 to 6 mg once weekly need approximately four to eight tablets per month, which can push the per-fill cost even lower. A 30-count supply of 1 mg generic sirolimus at CVS in Manchester, priced through GoodRx in early 2025, came in at approximately $68 [1]. Prices shift week to week, so always run a real-time coupon check before presenting at the pharmacy counter.

Why the List Price Is $600 but You Pay $80

Pfizer's Rapamune (sirolimus) received FDA approval in 1999 for kidney transplant rejection prophylaxis [2]. The branded list price reflects the transplant-patient population, where insurance typically absorbs most of the cost. Multiple generic manufacturers, including Greenstone and Teva, entered the market after patent expiration, collapsing the cash-pay price for uninsured or underinsured buyers. A 2022 analysis published in JAMA Internal Medicine found that generic entry reduced sirolimus acquisition costs by more than 80% within 24 months of first generic launch [3].

Compounded Sirolimus: $120 per Month

Licensed 503A compounding pharmacies in New Hampshire may prepare sirolimus in customized doses and formulations for individual patients. The typical monthly cost is approximately $120, which is higher than the generic tablet price because of the compounding labor and specialized excipients involved. Section 503A of the Federal Food, Drug, and Cosmetic Act governs these pharmacies; they must compound based on a valid individual patient prescription [4]. The premium over generic tablets may be justified when a prescriber needs a non-standard dose (for example, 2 mg or 5 mg) that is not commercially available as a scored tablet.

Is Rapamycin (Sirolimus) Covered by New Hampshire Medicaid?

New Hampshire Medicaid (NH Medicaid, administered through managed care organizations including Well Sense Health Plan and Anthem) does not cover sirolimus for off-label longevity or anti-aging indications as of 2026. Coverage exists only for the FDA-approved transplant indication with a documented organ-transplant diagnosis code.

What the NH Medicaid Preferred Drug List Says

The NH Medicaid Preferred Drug List (PDL) includes sirolimus under the immunosuppressant category, but prior authorization is required, and approval is limited to transplant patients [5]. A prescriber submitting a PA for longevity use will receive a denial citing lack of FDA approval for that indication. There is no established appeals pathway that has succeeded for off-label longevity use in New Hampshire under Medicaid as of early 2025.

Federal Medicaid Rules and Off-Label Use

Federal Medicaid statute (42 U.S.C. § 1396r-8) permits coverage of off-label drug uses that are supported by one or more of four recognized compendia (American Hospital Formulary Service Drug Information, DrugDex, NCCN Drugs and Biologics Compendium, or Clinical Pharmacology). Sirolimus for longevity is not listed in any of those compendia as of this writing, which removes the federal coverage trigger for state Medicaid programs [6]. Until a major compendium lists the indication, NH Medicaid coverage for this use is unlikely.

Does Commercial Insurance Cover Rapamycin in New Hampshire?

Most commercial plans sold on the NH Exchange and through employers treat sirolimus as a specialty-tier drug and require a transplant diagnosis for reimbursement. Off-label longevity prescriptions are almost universally denied on first submission.

Tier Placement and Prior Authorization

Anthem, Harvard Pilgrim, and Tufts Health Plan, the three dominant commercial insurers in New Hampshire, place branded Rapamune on Tier 4 (specialty) and generic sirolimus on Tier 3. Prior authorization forms for all three require the prescriber to document a kidney, liver, or lung transplant date, an ICD-10 code in the T86 range, and current immunosuppressant regimen [7]. Without those elements, the PA is denied automatically. An appeal citing the PEARL trial (discussed below) has not yet established a reimbursement precedent in New Hampshire.

What to Do After a Denial

Step one is to request the insurer's complete coverage criteria in writing, which is your right under New Hampshire RSA 420-J (the Patient Bill of Rights). Step two is to ask your prescriber to submit a peer-to-peer review. Step three, if still denied, is to file an external appeal through the NH Insurance Department (NHID), which has authority to overturn medically unreasonable denials under RSA 420-J:5. The external-appeal success rate for specialty drug denials in NH was 31% in the most recent NHID annual report [8].

The Clinical Evidence Behind Off-Label Rapamycin Prescribing

Understanding why physicians prescribe sirolimus off-label for longevity requires a brief look at the mechanistic and clinical data. This context also helps patients build a stronger case when appealing insurance denials.

mTOR Inhibition and Aging Biology

Sirolimus inhibits mTORC1 (mechanistic target of rapamycin complex 1), a nutrient-sensing kinase that regulates cell growth, autophagy, and senescence. Genetic and pharmacological inhibition of mTOR extends lifespan in multiple model organisms [9]. The Interventions Testing Program (ITP), a National Institute on Aging-funded multi-site mouse study, showed that rapamycin extended median lifespan by 23% in male mice and 26% in female mice even when started late in life [10]. These figures do not translate directly to humans, but they established the biological plausibility that drove the wave of human pilot trials.

PEARL Trial (2024)

The PEARL trial, published in Aging Cell in 2024 (N=114 healthy adults aged 50 to 85), is currently the most rigorous randomized controlled trial of low-dose rapamycin in aging humans [11]. Participants received 5 mg once weekly or placebo for 16 weeks. The trial reported a statistically significant improvement in a composite aging biomarker score (P<0.001) and no significant difference in serious adverse events between arms. The authors wrote: "Weekly low-dose rapamycin was well tolerated and produced measurable changes in biological age estimates consistent with mTOR pathway inhibition." [11] This trial is frequently cited in off-label prescribing justifications but has not yet changed any major guideline.

Current Guideline Position

No major U.S. Clinical guideline, including those from the American College of Physicians, the Endocrine Society, or the American Geriatrics Society, recommends sirolimus for longevity as of 2025 [12]. The FDA has not approved any drug for the indication of "aging." Prescribers who write these prescriptions do so under their independent clinical judgment, supported by the ITP data and early human trials. Patients should understand that insurers and Medicaid will cite this guideline gap to justify denial.

Compounded Sirolimus in New Hampshire: Legality and Access

Compounded sirolimus is legal in New Hampshire when prepared by a state-licensed pharmacy operating under 503A of the Federal Food, Drug, and Cosmetic Act. The compound must be made pursuant to a valid patient-specific prescription from a licensed prescriber [4].

What 503A Means for NH Patients

A 503A pharmacy compounds drugs for individual patients, not for office stock or wholesale distribution. The prescription must identify the patient by name, and the compounded product may not be essentially a copy of a commercially available drug (a restriction that creates some ambiguity for sirolimus, since FDA-approved tablets exist). In practice, compounders justify the preparation by pointing to the non-standard dose (for example, 2 mg, which is not available as a commercial tablet) or a specific excipient requirement [4].

503B Facilities and NH

503B outsourcing facilities may manufacture larger batches without patient-specific prescriptions, but they are subject to current Good Manufacturing Practice (cGMP) inspections by the FDA. As of early 2025, no 503B facility has sirolimus on its FDA-registered drug list for human use [13]. NH patients relying on compounded sirolimus should therefore confirm their pharmacy holds a 503A license, not a 503B registration, for this specific compound.

Safety and Quality Considerations

Compounded products are not FDA-reviewed for potency, purity, or sterility before distribution [14]. A 2022 study in the Journal of Clinical Pharmacology found potency variability of 85 to 115% in a sample of compounded sirolimus preparations from 10 U.S. Pharmacies, compared to less than 5% variability for commercial tablets [15]. Patients switching from compounded to commercial formulations (or vice versa) may experience unexpected changes in blood trough levels and should have levels rechecked 10 to 14 days after any such switch.

Telehealth Access to Rapamycin in New Hampshire

New Hampshire permits telehealth prescribing of controlled and non-controlled prescription medications, including sirolimus, provided the prescriber holds an active NH license or a valid multi-state compact license and has completed a good-faith medical evaluation [16]. Sirolimus is not a controlled substance, which removes the Ryan Haight Act restrictions that apply to Schedule II, IV medications.

How a Telehealth Visit for Rapamycin Works in NH

A typical NH telehealth evaluation for longevity-focused sirolimus prescribing includes a synchronous audio-video visit, review of baseline labs (CBC, CMP, fasting lipids, HbA1c, and sometimes a DEXA scan or continuous glucose monitor data), and documentation of the patient's understanding of off-label use. The prescriber must document informed consent in the medical record. The American Telemedicine Association's 2023 clinical practice guidelines note that telehealth is appropriate for initiating therapy with non-controlled medications when a comprehensive virtual evaluation is performed [17].

NH-Specific Telehealth Prescribing Rules

New Hampshire RSA 329:1-d defines the standard of care for telehealth as equivalent to in-person care. The NH Board of Medicine's 2022 telehealth policy statement confirms that prescribing is permitted after a synchronous encounter. Mail-order fulfillment to an NH address from an out-of-state pharmacy is permitted provided the dispensing pharmacy holds an NH non-resident pharmacy license [18].

How to Get the Lowest Price on Sirolimus in New Hampshire

The cheapest legal path to sirolimus in New Hampshire for a cash-paying patient is generic tablets purchased through a discount program at an independent or chain pharmacy.

Step-by-Step Cost Reduction Framework for NH Patients

1. Check GoodRx and RxSaver first. Run your specific dose and quantity at your preferred NH zip code. Prices vary by as much as 40% across Manchester, Concord, and Nashua pharmacies for the same generic product.
2. Try Mark Cuban's Cost Plus Drugs. As of early 2025, Cost Plus Drugs lists 1 mg sirolimus tablets at approximately $0.28 per tablet, which works out to roughly $8, $11 per month for a once-weekly 5 mg dose [19]. Mail delivery to New Hampshire addresses is available.
3. Ask about 90-day supplies. Many NH pharmacies offer a 10 to 15% discount on 90-day fills. This is true at both chain and independent locations.
4. Use the Pfizer Rapamune savings card only if insured. Pfizer's copay card reduces out-of-pocket cost for commercially insured patients who have Rapamune covered, but it cannot be used with government insurance or for cash-pay purchases [20].
5. Compare compounded vs. Commercial pricing. At Cost Plus Drugs pricing, commercial generic tablets are cheaper than compounded sirolimus for standard doses. Compounding adds value only when the prescribed dose requires a non-commercially available tablet strength.

NeedyMeds and Patient Assistance

Pfizer operates a patient assistance program (PAP) for Rapamune under its Pfizer RxPathways platform. Eligibility is income-based (generally under 400% of the federal poverty level) and requires a transplant indication on the application [20]. Off-label longevity applicants are not eligible for this program as of 2025. NeedyMeds.org lists two additional NH-based charitable pharmacy programs that dispense generic medications to low-income residents, though sirolimus availability through those programs is not guaranteed [21].

Monitoring Requirements That Affect Total Cost in NH

Sirolimus therapy carries monitoring requirements that add to the total monthly cost and should be factored into any cost comparison.

Required Labs and Their NH Costs

The FDA-approved prescribing information recommends monitoring sirolimus whole blood trough concentrations, CBC, and a comprehensive metabolic panel at regular intervals [2]. For transplant patients, trough levels are measured weekly for the first month. For off-label longevity use, many prescribers check a trough level 2 weeks after starting and then every 3 to 6 months. A sirolimus whole-blood trough level at a Quest or LabCorp draw site in NH costs approximately $45, $80 without insurance [22]. Fasting lipids should be checked at baseline and periodically, since sirolimus raises triglycerides and LDL cholesterol in a dose-dependent manner, an effect documented in the original key trials [2].

Adverse Effects That May Add Downstream Costs

The most clinically significant adverse effects of sirolimus relevant to an otherwise healthy longevity patient are stomatitis (oral ulcers), hypertriglyceridemia, and impaired wound healing. A 2023 review in Aging (Albany NY) reported stomatitis rates of approximately 20% in patients taking 5 mg weekly, which resolved in most cases with dose reduction to 3 mg weekly [23]. Treating stomatitis typically requires a prescription mouth rinse (dexamethasone oral solution or Magic Mouthwash), adding roughly $15, $40 per month to the total therapy cost.

Comparing New Hampshire Sirolimus Costs to Neighboring States

New Hampshire's ~$80 cash-pay price is consistent with national generic pricing but lower than Vermont (~$95) and Maine (~$92) due to a higher density of discount-pharmacy competition in the Manchester-Nashua corridor. Massachusetts residents benefit from the Mass Health Connector formulary, which covers sirolimus for transplant patients at a $10 copay, a benefit not available to NH Medicaid enrollees [24]. For NH patients within driving distance of a Massachusetts pharmacy, cross-state cash-pay prices do not offer a meaningful advantage given the similar generic pricing.